title: Clinical outcomes for sirolimus-eluting stents and polymer-coated paclitaxel-eluting stents in daily practice: results from a large multicenter registry.
abstract: OBJECTIVE
  We compared the clinical outcome of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in a real-world scenario.
  
  
  BACKGROUND
  In selected patients, SES has been associated with lower late luminal loss than PES. Whether this emerging biological difference could translate into different clinical efficacy in daily practice is presently unknown.
  
  
  METHODS
  This analysis included 1,676 consecutive patients with de novo coronary lesions treated solely with drug-eluting stents (SES = 992; PES = 684). All patients were enrolled in a dynamic prospective registry comprising 13 hospitals. We assessed the cumulative incidence of major adverse cardiac events (MACE), defined as death, myocardial infarction (MI), and target vessel revascularization (TVR) during follow-up.
  
  
  RESULTS
  Overall, 29% of the patients had diabetes, 23% had prior MI, and 9% had poor left ventricular function. ST-segment elevation MI was diagnosed at admission in 12%. Multivessel intervention was performed in 16%. At 1-year follow-up, SES was associated with a reduced incidence of MACE (9.2% SES vs. 14.1% PES; p = 0.007) and TVR (5.0% SES vs. 10.0% PES; p = 0.0008) compared to PES. A propensity analysis with many clinical and angiographic variables was carried out to adjust for baseline differences. In this analysis, SES was associated with a 44% risk reduction of MACE (hazard ratio 0.56, 95% confidence interval 0.39 to 0.78) and a 55% reduction of TVR (hazard ratio 0.45, 95% confidence interval 0.29 to 0.70). This result was consistent across most subgroups tested. Similar rates of death and MI were observed in the 2 treatment groups.
  
  
  CONCLUSIONS
  In this large real-world population, SES improved 1-year clinical results as compared to PES.
authors.affiliation: Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy. francescosaia@hotmail.com
authors.forename: Francesco
authors.initials: F
authors.lastname: Saia
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Piovaccari
authors.forename: Antonio
authors.initials: A
authors.lastname: Manari
authors.forename: Andrea
authors.initials: A
authors.lastname: Santarelli
authors.forename: Alberto
authors.initials: A
authors.lastname: Benassi
authors.forename: Enrico
authors.initials: E
authors.lastname: Aurier
authors.forename: Pietro
authors.initials: P
authors.lastname: Sangiorgio
authors.forename: Fabio
authors.initials: F
authors.lastname: Tarantino
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Geraci
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Vecchi
authors.forename: Paolo
authors.initials: P
authors.lastname: Guastaroba
authors.forename: Roberto
authors.initials: R
authors.lastname: Grilli
authors.forename: Antonio
authors.initials: A
authors.lastname: Marzocchi
mesh_terms: D000368:Aged; D023921:Coronary Stenosis / Q000628:therapy*; D003625:Data Collection; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control; D017239:Paclitaxel / Q000008:administration & dosage*; D011108:Polymers; D011446:Prospective Studies; D012042:Registries / Q000706:statistics & numerical data; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D016896:Treatment Outcome
chemical_list: D011108:Polymers; D017239:Paclitaxel; D020123:Sirolimus